Infusion Pump Market: as BD’s installed base of Alaris infusion pumps faces successive 2025 quality actions, from a software correction through a Class I recall to a safety communication about physical damage risk, the market’s largest incumbent platform is absorbing a sustained trust cost precisely while competitors’ newer, more tightly integrated systems reach the market, so hospital purchasing committees replacing or expanding infusion capacity increasingly weigh platform quality track record alongside integration features.

The global infusion pump market size was USD 12.64 Billion in 2025 and is expected to register a revenue CAGR of 6.1% during the forecast period. Market revenue growth is driven by factors such as continued expansion of Baxter’s integrated Novum IQ platform, BD’s Advanced Patient Monitoring integration strategy following its Edwards Lifesciences Critical Care acquisition, and the broader industry shift toward closed-loop medication and fluid delivery systems that combine infusion pumps with hemodynamic monitoring technology. The first driving factor is Baxter’s completion of its integrated Novum IQ infusion platform, extending smart pump capability with dose error reduction software across its full infusion product line. Baxter received US FDA 510(k) clearance for the Novum IQ Large Volume Infusion Pump with Dose IQ Safety Software, completing its integrated Novum IQ platform, and reported USD 1.1 Billion in Infusion Therapies and Technologies segment revenue in 2024, reflecting the platform’s commercial scale. The second driving factor is BD’s strategic integration of hemodynamic monitoring technology with its infusion pump platform following its acquisition of Edwards Lifesciences’ Critical Care product group. BD acquired Edwards Lifesciences’ Critical Care product group for USD 4.2 billion in an all-cash transaction, renaming it BD Advanced Patient Monitoring, whose hemodynamic monitoring technologies are routinely used simultaneously with the BD Alaris Infusion System in operating rooms and ICUs, enabling future closed-loop medication and fluid delivery capability. The third driving factor is the broader industry shift toward closed-loop systems that combine infusion delivery with real-time physiological monitoring to enable dynamically adjusted fluid and medication administration. These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way an infusion pump platform’s installed base widens its own vulnerability to a single quality event as more hospitals depend on the same platform for critical medication delivery, meaning a manufacturer with the largest installed base carries proportionally larger regulatory and reputational exposure when a quality issue emerges, while a manufacturer successfully avoiding such issues can convert platform quality reputation directly into new hospital contract wins. Once an infusion pump platform reaches a large installed base across many hospital systems, any subsequent quality issue affecting that platform, whether a software correction or a physical recall, has a correspondingly larger effect on market trust than an equivalent issue at a smaller-installed-base competitor, so installed base scale and quality event exposure are directly linked in a way that creates genuine competitive vulnerability for the largest incumbent platforms specifically. As a result, demand and revenue share are concentrating around vendors that can demonstrate both platform integration sophistication and a clean recent quality and regulatory track record, and the forecast tilts toward newer, more tightly validated systems as hospitals weigh platform trust alongside features when making replacement and expansion purchasing decisions. For instance, throughout 2025, BD’s Alaris infusion pump platform, the market’s largest installed base, experienced a February 2025 software correction addressing outdated automated programming requests, a Class I voluntary recall of pump infusion sets initiated in July 2025 and expanded through September 2025, and a subsequent safety communication in late 2025 regarding physical damage risk from dropped pump units, illustrating how a large installed base can face sustained, sequential quality scrutiny within a single year. These are some of the key factors driving revenue growth of the market.

The clearest driver of demand is Baxter’s completion of its integrated Novum IQ infusion platform, extending dose error reduction software capability across a unified product architecture. A unified platform architecture allows dose error reduction software validated on one pump type to extend more efficiently to additional pump types within the same platform family, and this is what completing the Novum IQ platform specifically enables, so platform completion and expanded smart pump capability rollout are directly linked. Baxter received US FDA 510(k) clearance for the Novum IQ Large Volume Infusion Pump with Dose IQ Safety Software, completing its integrated Novum IQ platform, and reported USD 1.1 Billion in Infusion Therapies and Technologies segment revenue in 2024, establishing the commercial scale of the platform Baxter has built. The effect on the market is that Baxter’s completed platform architecture positions the company to compete directly for hospital infusion fleet replacement decisions, particularly at institutions currently reassessing platform vendor relationships. These are some of the key factors driving revenue growth of the market.

The second driver is BD’s strategic combination of infusion pump technology with hemodynamic monitoring capability, enabling a closed-loop delivery model that neither technology alone can achieve. Closed-loop medication and fluid delivery requires both a monitoring technology to detect a patient’s real-time physiological state and a delivery technology to adjust dosing accordingly, and BD’s acquisition specifically combines both capabilities under one company, which is why this transaction is structurally different from a typical product line extension. BD acquired Edwards Lifesciences’ Critical Care product group for USD 4.2 billion in an all-cash transaction completed on September 3, 2024, renaming it BD Advanced Patient Monitoring, whose hemodynamic monitoring technologies are routinely used simultaneously with the BD Alaris Infusion System in operating rooms and ICUs. The effect on the market is that BD is positioned to be the first infusion pump vendor to bring genuine closed-loop delivery capability to market at scale, assuming successful integration of the acquired monitoring technology with its existing infusion platform. These are some of the key factors driving revenue growth of the market.

“BD’s Alaris infusion pump organizational unit continues to operate under an amended FDA consent decree originally entered into by Cardinal Health 303 in 2007, a regulatory history now compounded by a 2025 sequence of a software correction, a Class I recall, and a safety communication regarding physical damage risk to the pump bezel assembly.”

The third driver, functioning simultaneously as a demand catalyst for competitors and a genuine near-term challenge for BD specifically, is the sequence of quality and regulatory actions BD’s Alaris platform experienced through 2025. A platform with the largest installed base in a category faces proportionally larger scrutiny when quality issues emerge, since more hospitals and more patients are affected by any given issue, and this scale-driven exposure is a structural feature of holding market leadership position, not a one-off event, so BD’s installed base scale and its 2025 quality action sequence are directly connected. On February 18, 2025, BD and its subsidiary CareFusion issued an Urgent Medical Device Product Correction addressing outdated automated programming requests in Alaris Systems Manager software, followed by a Class I voluntary recall of BD Alaris Pump Module infusion sets initiated in July 2025 and expanded in September 2025, and a subsequent FDA safety communication in December 2025 regarding physical damage risk to pump bezel assemblies from dropped units. The effect on the market is that competing infusion pump vendors, including Baxter and ICU Medical, are positioned to capture hospital fleet replacement and expansion decisions from institutions reassessing their Alaris-dependent infusion infrastructure during this period of sustained BD platform scrutiny. These are some of the key factors driving revenue growth of the market.

However, the infusion pump market faces adoption constraints from the sustained regulatory and reputational exposure that BD’s Alaris platform has absorbed through 2025, the substantial capital cost of hospital-wide infusion platform replacement, and the integration complexity smart pump dose error reduction software requires with hospital-specific electronic health record and drug library systems. Because BD’s Alaris infusion pump organizational unit continues to operate under an amended FDA consent decree originally entered into by Cardinal Health 303 in 2007 and amended in 2009 to cover all CareFusion 303-manufactured infusion pumps, and because the platform experienced a sequential set of 2025 quality actions, an Urgent Medical Device Product Correction in February addressing outdated automated programming requests, a Class I voluntary recall initiated in July and expanded through September addressing pump infusion set performance, and a December safety communication regarding physical damage risk from dropped pump units, hospitals with large existing Alaris installed bases face genuine uncertainty about the platform’s near-term regulatory trajectory and must weigh this uncertainty against the substantial cost of platform replacement. Hospital capital cost of full platform replacement is a second constraint, since infusion pumps represent a large-scale, hospital-wide capital investment involving thousands of individual pump units across a health system, and switching an entire infusion pump fleet to a different vendor’s platform is a multi-year, high-cost undertaking involving procurement, staff retraining, and EHR integration rework that most hospitals cannot execute quickly even where accumulating quality concerns might otherwise justify a switch. Integration complexity with existing electronic health record and clinical workflow systems is the third constraint, since smart pump dose error reduction software must integrate accurately with hospital-specific drug libraries, dosing limits, and EHR systems to function safely, and this integration work adds implementation time and cost regardless of which vendor’s platform a hospital selects, meaning even a hospital motivated to switch platforms for quality reasons faces a lengthy, resource-intensive transition process. These factors substantially limit infusion pump market growth over the forecast period.

Based on product, the global infusion pump market is segmented into large volume infusion pumps, ambulatory/syringe infusion pumps, and patient-controlled analgesia (PCA) pumps. Large volume infusion pumps hold the largest revenue share, because they represent the core infusion capacity underlying most hospital inpatient and ICU fluid and medication delivery, which suits both Baxter’s Novum IQ platform and BD’s Alaris installed base. Ambulatory/syringe infusion pumps remain established for lower-volume, more precise medication delivery applications, and they command a meaningful share of oncology and specialty infusion use cases, but they cannot match large volume pumps’ overall installed base scale. Patient-controlled analgesia (PCA) pumps are expected to register steady revenue growth in the global infusion pump market over the forecast period, driven by continued post-surgical and oncology pain management demand, though this category remains smaller in absolute revenue than the large volume and ambulatory segments.

Critical care and hemodynamic monitoring integration application is expected to account for the fastest-growing revenue share in the global infusion pump market during the forecast period

Based on application, the global infusion pump market is segmented into general/fluid infusion, chemotherapy and oncology infusion, and critical care and hemodynamic monitoring integration applications. General/fluid infusion holds the largest revenue share, reflecting its position as the highest-volume, most universal infusion application across virtually every hospital department. Critical care and hemodynamic monitoring integration is expected to register the fastest revenue growth rate in the global infusion pump market over the forecast period, driven directly by BD’s Advanced Patient Monitoring integration strategy following its Edwards Lifesciences Critical Care acquisition, which is why closed-loop delivery capability represents the leading edge of infusion pump platform innovation.

Based on technology, the global infusion pump market is segmented into smart pumps with dose error reduction software and standard/non-integrated pumps. Smart pumps with dose error reduction software hold the largest revenue share, because dose error reduction functionality has become a standard hospital procurement requirement given its documented medication safety benefit, which suits both Baxter’s Dose IQ Safety Software and BD’s Alaris platform architecture. Standard/non-integrated pumps remain in use primarily in lower-resource healthcare settings and older installed base equipment awaiting replacement, but new hospital procurement activity has largely shifted toward smart pump technology as the default specification.

Based on regional analysis, the infusion pump market in North America accounted for largest revenue share in 2025. The United States leads because it hosts the largest installed base of both Baxter’s and BD’s infusion pump platforms, and because the FDA consent decree governing BD’s Alaris manufacturing unit and the associated 2025 quality actions are specifically United States regulatory matters. Baxter’s Novum IQ platform completion and BD’s Advanced Patient Monitoring integration strategy both concentrate commercial activity first within the United States hospital infusion pump market. The concentration of both leading infusion pump vendors and FDA regulatory oversight in the United States also means new infusion platform technology and any associated quality actions are typically visible in the United States market first.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Germany, the United Kingdom, and France represent the three largest national infusion pump markets within Europe. B. Braun, headquartered in the region, maintains a strong European installed base, and national health system procurement cycles for infusion equipment sustain steady demand largely independent of the United States-specific BD Alaris regulatory matters. The result is steady rather than rapid growth, shaped more by established procurement infrastructure than by the platform-trust dynamics currently active in the United States market.

The market in Asia Pacific is expected to register a rapid revenue growth rate over the forecast period. China, Japan, and India represent the three largest national infusion pump markets within the region. Expanding hospital infrastructure investment and rising smart pump technology adoption in China and India are driving new demand from a comparatively lower installed base, leaving more room for growth than in the already-mature North America and Europe markets.

The market in Latin America is expected to register a moderate revenue growth rate over the forecast period. Brazil and Mexico represent the two largest national infusion pump markets within the region. Hospital networks in both countries are gradually adopting smart pump technology, and the indirect effects of Iran-US sanctions and the associated Strait of Hormuz shipping disruption have kept freight and import costs elevated for the specialised infusion pump systems that Latin American hospitals depend on through 2026, slowing adoption beyond the region’s main urban centres.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia and the UAE represent the primary commercial infusion pump markets within the GCC. The UAE is the most established infusion pump market on the continent given its concentrated private hospital infrastructure, while the wider Gulf states and broader African markets are still building the hospital infrastructure that smart pump technology adoption depends on.